Biological Signal Processing (BSP) has obtained CE mark for its HyperQ AD-100 device, which is basically an add-on device to an existing electrocardiogram (ECG) stress system.
BSP develops non-invasive cardiology diagnostic devices. The HyperQ system, which has both CE mark and FDA certification, uses computer analysis of ECG signals at a higher sensitivity, by applying an algorithm.
The new product allows commercially available ECG systems to use BSP’s HyperQ technology, which provides improved monitoring.
BSP said that the HyperQ AD-100 device can diagnose ischemic heart disease (damage to the arteries) with greater precision and sensitivity. The technology does not use radiation or cause any harm to the patient, and it does not require replacing current ECG systems used by physicians.
Nissim Greisas, CEO of BSP, said: “Combining HyperQ AD-100 systems with standard ECGs on the market greatly expands the company’s potential market.”